131I

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF MutationThyroid Cancer

Phase 2

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

CompletedNCT03244956

Gustave Roussy, Cancer Campus, Grand ParisMetastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Start: 2017-12-27End: 2026-01-15Updated: 2026-03-23

Unknown Phase

A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

CompletedNCT01736163

Genzyme, a Sanofi CompanyThyroid Cancer

Start: 2012-05-31End: 2012-08-31Updated: 2015-03-23